Precision Medicine

The explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.

We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:

  • Will testing change patient management for this indication?
  • If so, what tests and/or therapies should I use?
  • Should we cover testing and/or therapies?
  • Can we manage these services internally?

 

 

PancraGEN (Interpace Diagnostics)

The PancraGEN test is a molecular-based cancer diagnostic test that combines molecular genetic testing with current 

ProMark Proteomic Prognostic Test (Metamark Genetics Inc.)

An estimated 180,890 new cases of prostate cancer will be diagnosed in 2016, which accounts for 10.7% of all new cancer cases in the United States. Prostate cancer is the second leading cause of cancer death in the United States, with approximately 12.9% of men being diagnosed during their lifetime. For men diagnosed with prostate cancer from 2006 to 2012, the 5-year survival rate is 98.9%. Wh…

Sofosbuvir-Velpatasvir for Chronic HCV Infection

Purpose of Technology: Sofosbuvir-velpatasvir (Epclusa) is a “next-generation” once-daily direct-acting antiretroviral (DAA) combination oral regimen for the treatment of all 6 major hepatitis C virus (HCV) genotypes. The fixed-dose combination pill contains 400 mg of sofosbuvir and 100 mg of velpatasvir.

Whole Genome Sequencing (WGS) in Neonatal and Pediatric Patients

This report examines the clinical utility of whole genome sequencing (WGS) in neonatal and pediatric populations. Given the recent emergence of the technology, there is considerable interest in its clinical use and ability to identify deleterious variants not always identified through traditional diagnostic metho…

Genetic Testing for Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)

This report examines the clinical utility of genetic testing for diagnosis of hereditary leiomyomatosis and renal cell cancer (HLRCC) in symptomatic patients and their at-risk family members. The evidence for the use of genetic testing is evaluated with respect to screening for potential HLRCC patients, renal cancer surveillance and early detection, and the fertility impact of and morbidity fr…

SLCO1B1 Pharmacogenomic Genotyping for Statin Dosing or Selection

This report examines the clinical utility of genotyping for SLCO1B1 variants in pediatric or adult patients needing treatment with a statin to reduce low-density lipoprotein cholesterol. The evidence for the use of genetic testing is evaluated with respect to selecting statin type or dose in order to improve statin prescribing and patient adherence, and to avoid adverse events such as s…

Whole Exome Sequencing for Neurological Conditions in Pediatric Populations

With the recent advances in whole exome sequencing (WES) technologies, there has been considerable interest in its clinical application. This report assesses the evidence for the use of WES for neurological conditions in pediatric populations after standard diagnostic and genetic tests failed to provide a definitive diagnosis. The goal of the report is to assess the clinical utility of WES, in…

Epi proColon (Epigenomics Inc.)

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths in the United States. It is estimated that approximately 134,000 individuals will be diagnosed with CRC in 2016, and approximately 49,000 people will die from the disease. It is established that screening for CRC allows for the early detection and removal of cancers or precancerous …

DecisionDx-UM (Castle Biosciences Inc.)

 

Uveal melanoma (UM) is the most common form of primary eye cancer. The incidence of UM in the United States is approximately 4.3 cases per million. UM is more common in older individuals, with incidence rates peaking at age 70, and is associated with characteristics such as fair skin and eye color. UM affects the iris, ciliary body, and choroid portions of the uveal tract, the mi…

VeriStrat

Non-small cell lung cancer (NSCLC) encompasses squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. In the United States in 2015, it is estimated that NSCLC was diagnosed in more than 221,000 individuals and resulted in more than 158,000 deaths. More than 80% of lung cancer patients have NSCLC. The VeriStrat test relies on matrix-…